Hunton Andrews Kurth Continues Global Energy Team Expansion in London
One Year of Sustained Local Growth Includes More Than Two Dozen Lawyers
Hunton Andrews Kurth LLP continues to expand in London with the addition of nearly a dozen highly regarded energy and project finance lawyers.
Partners Charles Morrison, Dimitri Papaefstratiou, Simon Collier, Harry Brunt, Counsel Joseph Lam, and ConsultantGrant Henderson, along with five associates, have joined the firm from Ernst & Young’s legal services arm, EY Law. The team focuses on transactions in various energy sectors, such as oil and gas, renewable and thermal power, as well as emerging technologies of carbon capture, hydrogen and energy storage.
“The addition of these distinguished lawyers underscores our commitment to maintaining our position as a leading adviser to the global energy industry,” said Hunton Andrews Kurth Managing Partner Sam Danon. “The team aligns well with our international growth strategy, which is focused on ensuring that we’ve achieved critical mass in key practices, in core industry focus areas and in geographies where client demand is strong.”
“Energy sector activity remains incredibly robust, driven by the need for renewable and alternative solutions in support of the energy transition as well as the need for infrastructure and traditional resource development in emerging and mature economies,” added Jeff Schroeder, head of Hunton Andrews Kurth’s energy and infrastructure team. “We are particularly excited about the team’s capabilities to grow the pipeline of complex, cross-border energy projects and adding depth to our global energy practice.”
In support of its international growth strategy, since August 2023, Hunton Andrews Kurth has added more than two dozen lawyers to its London office. Most recently, finance Partners Alan Cunningham and Richard Skipper joined the firm from EY Law. In September, the firm added project finance Partners Ayesha Waheed and Seyfi Can Kandemir. Last year, Hunton Andrews Kurth welcomed to Londoncorporate energy Partner Philip Mace and energy and infrastructure disputes Partners Maurice Kentonand David Hesse, Counsel Edward Hamiltonand Special Counsel Simon Schooling, who collectively are leading members of the firm’s international arbitration team.
“Our energy-focused corporate and disputes teams in London have experienced tremendous growth over the past year, expanding our reach throughout Europe, the Middle East and Africa,” said Ferdinand Calice, managing partner of Hunton Andrews Kurth’s London office. “We are pleased to welcome our newest colleagues to the firm.”
About Hunton Andrews Kurth’s Energy and Infrastructure Team
Hunton Andrews Kurth’s global energy and infrastructure lawyers assist clients in bringing some of the world’s largest and most complex projects to market. Our team provides concept-to-close advice on the development and financing of capital-intensive projects. We represent sponsors, lenders, investors, governments, and other project participants operating in virtually every segment of the energy industry and infrastructure industry. Our projects attorneys have handled transactions in more than 75 countries, with market leading strengths in project finance, agency finance, commercial nuclear power, U.S. energy tax credits, subsea fiber-optic networks, and utility capital markets, among many others.
About Hunton Andrews Kurth LLP
For more than 120 years, Hunton Andrews Kurth has served clients across the globe with a collaborative and purposeful approach. With offices strategically located in the United States and around the world, the firm is known for its strength in the energy, financial services, real estate, and retail and consumer products industries, as well as its considerable depth across numerous practice areas. Hunton Andrews Kurth fosters a strong culture built upon an unwavering commitment to its clients, colleagues, and communities. To learn more, please visit huntonak.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211423314/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom